21173-Breast Cancer-NA-564

Breast Cancer

A Phase 3, double-blind, randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

  • Details

ClinicalTrials.gov ID: NCT04964934
Diagnosis Type: NA
USOR Number:

  • Address

8820 Huron St
Thornton, CO 80260
P: (303) 386-7622

Search by practice name, trial titles, indicators and specific disease types.